Human Serum, Pre SARS-CoV-2

Host: Human
Product: Serum, Pre SARS-CoV-2
Conjugate: Unconjugated
Product Category: Normal Serums and Gamma Globulins

Collected: Pre August 2019

Code: 009-000-243

Unit:
1.0 ml

Price:
$69.00

Download GHS/SDS

Technical Info

Need Assistance?

Technical
Inquiry Product
Selection

Information

Serum is lipid extracted to improve clarity, dialyzed against phosphate buffered saline (PBS), and freeze dried. Serum was collected before August 2019, prior to SARS-CoV-2 pandemic, and tested by ELISA for antibodies to SARS-CoV-2 Spike S1 Receptor Binding Domain (RBD).

Usage

Physical State: Freeze-dried solid

Storage and Rehydration: Store freeze-dried solid at 2-8°C. Rehydrate with the indicated volume of dH2O (see product specification sheet) and centrifuge if not clear. Prepare working dilution on day of use. Aliquot and freeze undiluted product at -20°C or below. Avoid repeated freezing and thawing.
Expiration date: one year from date of rehydration. The expiration date may be extended if test results are acceptable for the intended use.

Buffer: 0.01M Sodium Phosphate, 0.25M NaCl, pH 7.6
Preservative: None. Product is not sterile, but may be sterile-filtered or a preservative may be added.

Suggested Working Concentration or Dilution Range:
1:100 - 1:400 for SARS-CoV-2 antibody ELISAs. Dilution should be optimized for assay of interest. Rehydration according to instruction yields 100% serum.

Images & References

* Apparent antibody concentration quantified compared to a standard curve generated with SARS-CoV-2 Spike S1 Antibody (HC2001) – Genscript A02038-100 Figure legend: ELISA for SARS-CoV-2 antibodies from human serum was carried out as described in Amanat et al. (2020) with the following modifications: Coating/capture material: SARS-CoV-2 Spike Protein RBD (Genscript – Z03483-100) diluted to 2 µg/ml in PBS, and 50 µl (2 µg/well) was coated onto an ELISA plate overnight at 4˚C. Plates were blocked with 1% Bovine Serum Albumin (IgG-Free, Protease-Free) (001-000-162) in PBS + 0.05% Tween-20 (PBST). Samples: Human IgG sourced pre-August 2019 [ChromPure Human IgG, whole molecule (009-000-003)] was diluted to 250 µg/ml in 1% BSA/PBST, in triplicate, (100 µl/well). Human Serum sourced pre-August 2019 (009-000-243) was diluted 1:150 in 1% BSA/PBST in triplicate (100 µl/well). Human serum confirmed to be SARS-CoV-2 naive was drawn from seven volunteers. Human serum deemed to be SARS-CoV-2 antibody positive (~ 26-37 days after exposure to SARS-CoV-2, confirmed diagnosis) was drawn from four individuals. Volunteer-derived human serum samples were diluted 1:150 in 1% BSA/PBST (100 µl/well). Detection: HRP-Conjugated secondary antibody (109-035-064) was diluted in PBST at 1:20,000 and added to each well (100 µl/well). Plates were incubated with TMB (Moss TMBHK-1000) for 30 minutes at room temperature. TMB was detected at 620 nm using a plate reader. Standard/calibration curve: Standard curves were generated using Human IgG SARS-CoV-2 Spike S1 Antibody (HC2001) (Genscript A02038). The antibody was serially diluted (1:3) in 1% BSA/PBST, in triplicate, across the ELISA plate starting at 200 ng/ml (100 µl/well). Analysis: Graphpad Prism 8 was used to fit non-linear regression curves to a standard curve generated using the anti-SARS-CoV-2 antibody. Results and apparent antibody concentrations (µg/ml) in serum were interpolated from the curves generated.

This product is for in vitro research use only. It is not a medical device and it is not intended for diagnostic or therapeutic purposes.